Teriparatide: Reference Overview and Reconstitution Notes

Teriparatide is a lab-made copy of a piece of the body's parathyroid hormone. It belongs to a group of compounds that help build bone, and it has FDA approval for a specific use related to bone loss.

Teriparatide

What it is

Teriparatide is a lab-made (recombinant) copy of the first 34 building blocks (amino acids) of a natural human hormone called parathyroid hormone. Scientists write this as PTH(1-34). It fits into a docking site on cells called the PTH1 receptor, and it is grouped with the osteoanabolic (bone-building) compounds. This entry describes what it is, its regulatory status, and how to handle it at the lab bench. It is not a usage guide.

Research context and categorization

Teriparatide belongs to the peptide hormone family. More specifically, it fits into the bone-building (osteoanabolic) or bone-metabolism category. Unlike compounds that slow bone breakdown, it is characterized as a bone-formation compound. Much of the research focuses on how the timing of exposure changes what it does.

One key observation in the literature: when parathyroid hormone is present continuously, it tends to favor breaking down old bone (a process called bone resorption). But when it is present in short bursts, once a day, it tends to shift the balance toward building new bone instead.

Key point: While continuous parathyroid hormone exposure favors bone resorption (breakdown), intermittent, once-daily exposure shifts the metabolic balance to favor new bone formation.

Because it is an approved medicine, its established use is set by its official labeling. Research has studied it in the context of osteoporosis (a condition where bones become thin and fragile) and bone mineral density (a measure of how solid and strong bones are). Scientists have also compared it to related molecules such as abaloparatide and romosozumab, and to biosimilar (near-identical copy) versions. Any bone-healing or tissue-repair topics discussed beyond its approved use are investigational and have not been confirmed or approved.

Status

• Regulatory status: FDA-approved for a specific use. Teriparatide (brand name Forteo, made by Eli Lilly) was approved in November 2002 for osteoporosis in people at high risk of fractures. Additional lab-made and biosimilar versions (for example Bonsity, approved 2019) have since come to market. Material sold by research supply vendors is labeled research-only and is a separate category from the approved drug product.
• Sport status: Prohibited under the WADA Prohibited List. As a peptide hormone, it is covered under the peptide hormones, growth factors, related substances, and mimetics class (S2). A Therapeutic Use Exemption may be considered where a documented medical need exists. Always confirm current status directly against the WADA Prohibited List, which is updated every year.

Reconstitution notes (general)

Reconstitution means dissolving a freeze-dried powder back into a liquid. Think of it like dissolving a bouillon cube in water. The concentration (how much peptide is in each milliliter of liquid) equals the amount of peptide in the vial divided by the volume of bacteriostatic water (a mild preservative water used in labs) added. For example, adding 2 mL of water to a 10 mg vial gives 5 mg/mL.

Adding less water gives a more concentrated solution. Adding more water gives a more dilute solution. The total amount of peptide in the vial stays the same either way. Use the calculator at peptide calculator to figure out a target concentration before drawing anything up.

Dilution and handling notes (compound-specific)

Two very different forms of teriparatide exist. How you handle it depends on which form you have in front of you.

Approved Injectable Format

The approved injectable comes as a ready-to-use liquid, not a powder. It is a sterile, colorless, clear solution at roughly 250 mcg/mL (micrograms per milliliter), already filled into a glass cartridge inside a single-patient, multi-dose pen.

The solution is kept at about pH 4.0 using an acetate system. pH is a scale from 0 to 14 that shows how acidic or basic something is. A pH of 7 is neutral, like pure water. Lower numbers are acidic (like vinegar), and higher numbers are basic. Mannitol (a sugar-like compound that helps keep the structure stable) and metacresol (a preservative) are also included. Nothing needs to be mixed. There is no reconstitution step for this form.

Research-Grade Lyophilized Format

Research-grade material usually ships as a lyophilized powder (freeze-dried, meaning the water has been removed under cold and low-pressure conditions) in a vial. It is dissolved in liquid before lab use. PTH(1-34) is a short, generally well-behaved peptide that dissolves easily in water-based solutions and does not clump or gel.

Because this compound is most stable in a mildly acidic environment, it dissolves best and stays stable at around pH 3 to 5. A slightly acidic diluent (the liquid used to dissolve it) supports it well. Neutral or basic conditions are less favorable.

Typical amounts of bacteriostatic water used to dissolve it range from roughly 1 to 3 mL per vial, depending on vial size and the concentration needed. Some multi-vial research kits arrive already premixed to about 1 mL.

Stability and Handling Quirks

One important quirk to know: once freeze-dried PTH(1-34) powder is dissolved into a solution, how stable it stays depends on concentration and storage temperature. Cloudiness or particles (called precipitation, like fine sediment settling in a liquid) can appear within roughly two to four weeks in some samples. By contrast, equivalent material that was never freeze-dried can stay clear for as long as about twelve weeks in liquid form.

Like most peptides, it is also sensitive to heat, shaking, and long exposure to light. It can break down over time through oxidation (a reaction with oxygen, similar to how cut fruit browns) and deamidation (a chemical change that alters its structure). Cloudiness, floating particles, or clumping signal that the compound has degraded, not that something went wrong during mixing.

When dissolving the powder, add the diluent gently down the inside wall of the vial and swirl gently rather than shaking, to keep foam from forming. Keep the dissolved solution cold and shielded from light.

Handling and storage

Follow these steps to keep the compound stable and avoid early breakdown:

• Store in a refrigerator at 2 to 8 degrees Celsius and keep it away from light.
• Wipe the rubber stopper with alcohol before each puncture, and write the mix date on the vial label.
• Use the reconstituted solution within roughly 4 weeks when kept refrigerated. This lines up with the labeled 28-day discard period for the in-use approved pen.
• Inspect the solution before every use. Discard it if it looks cloudy or discolored, or if you see any visible particles floating in it.

Related reading

• Tesamorelin
• Tirzepatide
• EPO
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What is teriparatide and how does intermittent vs continuous exposure affect bone metabolism in research models?

Teriparatide is recombinant PTH(1-34) that binds the PTH1 receptor. Research shows continuous exposure favors bone resorption, while intermittent once-daily exposure shifts the metabolic balance toward new bone formation.

Is teriparatide prohibited under the WADA Prohibited List?

Yes. As a peptide hormone it is classified under the S2 class (peptide hormones, growth factors, related substances and mimetics). A Therapeutic Use Exemption may apply where documented medical need exists. Confirm against the current annual list.

How is reconstitution concentration calculated when preparing a teriparatide research solution?

Divide the total peptide mass in the vial by the volume of bacteriostatic water added. Example: 10 mg dissolved in 2 mL yields 5 mg/mL. Less solvent increases concentration; more solvent dilutes it. Total peptide mass remains constant.

What the research community gets wrong about teriparatide handling

PTH(1-34) has a few handling habits that trip up even careful benches. Here are the ones worth knowing before you mix a vial.

• Freeze-dried does not mean it lasts longer once mixed. It is easy to assume a lyophilized powder gives a more stable solution than a ready-made liquid. Controlled work found the opposite: reconstituted lyophilized PTH(1-34) started to show cloudiness and particles within about two to four weeks in some samples, while matched material that was never freeze-dried stayed clear for as long as twelve weeks. The freeze and dry step itself changes the structure and makes it more likely to clump later.
• More concentrated is not safer. The rate of clumping and precipitation goes up as the peptide gets more concentrated. A more dilute solution often stays clear longer, so pushing a vial to a very high concentration can work against you.
• pH is doing more work than most people notice. This peptide holds up best in a mildly acidic setting, roughly pH 3 to 5. The approved product is kept at about pH 4 with an acetate system for this reason. Moving toward neutral or higher pH, and higher salt content, both speed up aggregation.
• Cloudiness is degradation, not a mixing mistake. If a solution turns hazy or shows floating specks after some storage time, that is the peptide aggregating and dropping out, not a sign you swirled it wrong. Inspect before each use and set aside anything that looks cloudy, discolored, or full of particles.
• Heat and shaking quietly break it down. Warmth, hard shaking, and lots of air contact all push the peptide toward clumping. Add diluent slowly down the inner wall, swirl gently instead of shaking, and keep the vial cold and out of the light.

From our bench: When teriparatide vials pass through our hardware for reconstitution testing, the pattern that matches the published stability work is the one we see too: solutions that were added gently down the vial wall and swirled stay visibly clear far longer than ones that got shaken, and once a vial goes hazy it does not clear back up. We keep every test vial dated and inspect it against a light before handling, since a side-by-side look against a fresh vial makes early cloudiness much easier to catch.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Merutka G, et al. Stability of lyophilized teriparatide, PTH(1-34), after reconstitution. Eur J Pharm Biopharm. 2016. PMID 26620825
5. PubChem Compound Summary: Teriparatide (CID 16133850), NIH National Library of Medicine
6. FORTEO (teriparatide injection) label , FDA/DailyMed (pH 4 acetate system, 2 to 8 C storage, 28-day in-use)